Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).

27 May 2010

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

If you're headed to a freshwater stream this summer and a friend dares you to eat a raw crayfish - don't do it. You could end up in the hospital with a severe parasitic infection.

27 May 2010

Blocking the activity of death receptor can stop tumor growth: New research study

Every cell contains machinery for self-destruction, used to induce death when damaged or sick. But according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumors.

27 May 2010

Experimental Hendra virus treatment offered to mother and daughter

After recent reports of a horse being put down for being infected with the deadly Hendra virus, new reports of an experimental treatment have surfaced. At Queensland's Sunshine Coast a mother and daughter duo, Rebecca Day and her 12 year old girl Mollie, who had been exposed to the virus, have been offered the experimental treatment.

27 May 2010

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

Lymphoma Foundation Canada (LFC) applauds Ontario's recent decision to publicly fund Rituxan (rituximab) in combination with Fludarabine-based chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL).

26 May 2010

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

26 May 2010

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

Italian researchers have discovered that antiviral treatment and sustained virologic response prevents esophageal varices in patients with compensated hepatitis C -induced cirrhosis, indicating that endoscopic surveillance can be safely delayed or avoided in these patients. Full findings are published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

26 May 2010

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed for reaching a clinical milestone under the license and collaboration agreement, entered into on July 11, 2008.

26 May 2010

Heptares Therapeutics, O2h extend multi-FTE -synthetic chemistry services collaboration

Executives from Heptares Therapeutics (Welwyn Garden City, UK) and O2h (Cambridge, UK) announced today an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

26 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.

25 May 2010

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

25 May 2010

Mayo Clinic becomes first hospital in the U.S. to discharge a patient with artificial heart

Mayo Clinic Hospital in northeast Phoenix made history on May 3, 2010, when it became the first hospital in the U.S. to discharge a patient with an artificial heart - after he had been hospitalized for more than two years.

25 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Scientists develop DNA-vaccine that restricts supply of blood to tumours

A DNA-vaccine that restricts the supply of blood to tumours has been developed by scientists at the Swedish medical university Karolinska Institutet. The vaccine slows the growth of breast cancer tumours in mice.

24 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

Immunome announces completion of financing by BioAdvance

Immunome, a discovery-stage antibody platform company focused on life-threatening infectious diseases, announced today the completion of a financing by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. The funding round also included private investors.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Antibody News and Research

Further Reading

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

Blocking the activity of death receptor can stop tumor growth: New research study

Experimental Hendra virus treatment offered to mother and daughter

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

New journal to focus on autoimmune disease research and development

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Heptares Therapeutics, O2h extend multi-FTE -synthetic chemistry services collaboration

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Mayo Clinic becomes first hospital in the U.S. to discharge a patient with artificial heart

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Scientists develop DNA-vaccine that restricts supply of blood to tumours

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Immunome announces completion of financing by BioAdvance

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo